Table 3. Baseline characteristics of patients with NSCLC in the training cohort, validation cohort, and the total population.
| Characteristic | Total | Training cohort | Validation cohort | P |
|---|---|---|---|---|
| Sex | 0.63 | |||
| Female | 31 (18.902) | 24 (18.182) | 7 (21.875) | |
| Male | 133 (81.098) | 108 (81.818) | 25 (78.125) | |
| Age (years) | 0.39 | |||
| >60 | 66 (40.244) | 51 (38.636) | 15 (46.875) | |
| ≤60 | 98 (59.756) | 81 (61.364) | 17 (53.125) | |
| Smoking status | 0.98 | |||
| Non-smoker | 67 (40.854) | 54 (40.909) | 13 (40.625) | |
| Smoker | 97 (59.146) | 78 (59.091) | 19 (59.375) | |
| KPS | 0.48 | |||
| >80 | 78 (47.561) | 61 (46.212) | 17 (53.125) | |
| ≤80 | 86 (52.439) | 71 (53.788) | 15 (46.875) | |
| Pathological type | >0.99 | |||
| Adenocarcinoma | 93 (56.707) | 75 (56.818) | 18 (56.250) | |
| Squamous carcinoma | 66 (40.244) | 53 (40.152) | 13 (40.625) | |
| Other | 5 (3.049) | 4 (3.030) | 1 (3.125) | |
| Oligometastasis | 0.52 | |||
| No | 125 (76.220) | 102 (77.273) | 23 (71.875) | |
| Yes | 39 (23.780) | 30 (22.727) | 9 (28.125) | |
| Clinical T stage | 0.54 | |||
| T1–2 | 49 (29.878) | 38 (28.788) | 11 (34.375) | |
| T3–4 | 115 (70.122) | 94 (71.212) | 21 (65.625) | |
| Clinical N stage | 0.40 | |||
| N0–1 | 20 (12.195) | 18 (13.636) | 2 (6.250) | |
| N2–3 | 144 (87.805) | 114 (86.364) | 30 (93.750) | |
| Clinical M stage | 0.70 | |||
| M0 | 108 (65.854) | 86 (65.152) | 22 (68.750) | |
| M1 | 56 (34.146) | 46 (34.848) | 10 (31.250) | |
| Clinical stage | 0.57 | |||
| I–II | 9 (5.488) | 8 (6.061) | 1 (3.125) | |
| III | 95 (57.927) | 74 (56.061) | 21 (65.625) | |
| IV | 60 (36.585) | 50 (37.879) | 10 (31.250) | |
| Invading mediastinal lymph nodes | 0.22 | |||
| No | 45 (27.439) | 39 (29.545) | 6 (18.750) | |
| Yes | 119 (72.561) | 93 (70.455) | 26 (81.250) | |
| Response status | 0.60 | |||
| CR + PR | 55 (33.537) | 43 (32.576) | 12 (37.500) | |
| PD + SD | 109 (66.463) | 89 (67.424) | 20 (62.500) | |
| Chemotherapy regimens | 0.23 | |||
| Platinum containing double drug | 131 (79.878) | 103 (78.030) | 28 (87.500) | |
| Other | 33 (20.122) | 29 (21.970) | 4 (12.500) | |
| The number of chemotherapy cycles administered during CCRT | 0.33 | |||
| <3 | 95 (57.927) | 74 (56.061) | 21 (65.625) | |
| ≥3 | 69 (42.073) | 58 (43.939) | 11 (34.375) | |
| CEA | 0.30 | |||
| Normal | 105 (64.024) | 82 (62.121) | 23 (71.875) | |
| Increase | 59 (35.976) | 50 (37.879) | 9 (28.125) | |
| NSE | 0.15 | |||
| Normal | 122 (74.390) | 95 (71.970) | 27 (84.375) | |
| Increase | 42 (25.610) | 37 (28.030) | 5 (15.625) | |
| CYFRA21-1 | 0.39 | |||
| Normal | 61 (37.195) | 47 (35.606) | 14 (43.750) | |
| Increase | 103 (62.805) | 85 (64.394) | 18 (56.250) |
CCRT, concurrent chemoradiotherapy; CEA, carcinoembryonic antigen; CR, complete response; CYFRA 21-1, cytokeratin 19 fragment; M, distant metastasis; N, regional lymph nodes; NSE, neuron-specific enolase; NSCLC, non-small cell lung cancer; PD, progressive disease; PR, partial response; SD, stable disease; T, tumor.